Skip to main content
| News

docdok.health involved in coronavirus research project

22.02.2021

A research project is investigating the improvement in the condition of patients who have been hospitalized due to COVID-19. docdok.health based in Basel is contributing the smartphone app for the project.

img: docdok.health

According to a media release, the new research project on the effects of coronavirus infection has been launched by the CAir Konsortium, which includes the University Hospital Zurich (USZ) and the Swiss Federal Institute of Technology in Zurich (ETH) in addition to docdok.health, among others. The media release from docdok.health states that the project is also being supported by AstraZeneca Switzerland. With this, the research partners hope to investigate “the improvement in symptoms, lung function and quality of life in persons who have been hospitalized due to a coronavirus (specifically SARS-CoV-2) infection and the related severe lung disease to lung failure.”

For this, patients were surveyed after being discharged from the USZ using a docdok.health smartphone app, and a home monitoring system was implemented to follow-up patients. This system consists of “a lung function measuring device, an activity wristband, an air quality monitor, and a smartphone.” This system, called CAir Desk, was originally developed for the long-term care of patients with chronic lung disease.

Physicians from the USZ are able to study the data from both approaches at their place of work. For this, the data is prepared by docdok.health and presented clearly on an appropriate user interface. The company based in Basel was founded in 2017 and develops solutions to drive forward utility-based healthcare. The platform they have developed can collect and prepare patient-generated health data. This platform is already in use in five countries both for routine clinical applications and studies.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

South Korean pharma firms show interest in the Basel Area
Basel Area Business & Innovation, Invest, Life Sciences / biotech, Switzerland Innovation Park

South Korean pharma firms show interest in the Basel Area

Several South Korean firms from the life sciences industry, including three pharmaceutical multinationals, have visited the Basel Area on fact-finding...

Read More
Gamma Technologies acquires ProFEMAG portfolio
Advanced Manufacturing/AI, Basel Area Business & Innovation, ICT, Innovation, Invest

Gamma Technologies acquires ProFEMAG portfolio

The Basel-based firm ProFEMAG AG has sold its FEMAG software for electrical machine applications to Gamma Technologies. The company based...

Read More
Databaum establishes headquarters in Basel
Basel Area Business & Innovation, ICT, Innovation, Invest, Life Sciences / biotech

Databaum establishes headquarters in Basel

Databaum is establishing its headquarters in Basel and plans to grow from its location there. The startup provides the agricultural...

Read More
Clinerion launches patient information platform
Basel Area Business & Innovation, Digital Health, ICT, Innovation, Invest, Life Sciences / biotech

Clinerion launches patient information platform

Basel-based Clinerion is introducing its machine learning platform. It comprises a global network of hospitals and enables researchers to recognize...

Read More
New innovation campus opens in the Basel Area
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech, Switzerland Innovation Park

New innovation campus opens in the Basel Area

The Main Campus of the Switzerland Innovation Park Basel Area was officially opened on October 29. In his speech, Federal...

Read More
Sumitovant acquires all shares in Myovant
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Sumitovant acquires all shares in Myovant

Sumitovant is in the process of making Basel-based Myovant Sciences a wholly owned subsidiary by acquiring a 100 percent shareholding...

Read More
1 2 3 29

Do you have a question? We'd like to hear from you.